Where Do Investors Buy? $AMGN Crushed On Drug Data And Cost
This article is published in collaboration with Scutify, where you can find real-time markets and stock commentary from Robert Marcin, Cody Willard and others. Download the Scutify iOS App, the Scutify Android App or visit Scutify.com.
Shares of Amgen, Inc. (NASDAQ:AMGN) took a thumping today after they announced slightly better data on a cholesterol drug, compared to its peers already on the market. The problem is, the drug costs $15,000 a year and insurance companies will likely not cover the drug because it is only slightly better than what is on the market. The stock dropped over 6% and many investors rushed to buy it. That is a mistake. The stock will continue to trend lower until it hits $160.00, a major support gap fill level. The reasoning is simple. First, investors should never buy a gap lower on negative news from a stock at all-time highs. There will be more trimming of positions in the hedge fund industry and possibly analysts downgrading the stock. In addion, there is no major technical support that is strong enough to justify a buy level. The $160.00 level is major. Buy it there.
View my trades and Verified performance right now, click here. Simply join Verified Investing for free and anytime I buy a stock/ETF, you will get an email. You can then opt-into the trade getting my exact entry price, target and stop. Those who take my trades, only reward me (a Verified Trader) with a few Dollars IF they get big winning trade information.
This article was written by Anna B for on .
Daily Recap Newsletter